Blog
>
IQ HealthTech's position on TALLman lettering
Industry insight

IQ HealthTech's position on TALLman lettering

The BOPA TALLman recommendations are a key step in standardising Tall Man lettering for SACT drugs in the UK. IQ HealthTech supports this and is committed to helping customers implement it in line with BOPA and ISMP standards. To ensure safety benefits are fully realised, consistent adoption across all clinical systems and suppliers is essential.

‍

In 2022, the British Oncology Pharmacy Association (BOPA) released recommendations for the use of TALLman lettering for for SACT (Systemic Anti-Cancer Treatment) treatments in the UK.  

IQ HealthTech supports the utilisation of Tall man lettering and is keen to work with its customers to implement Tall man as per the BOPA standards to allow full realisation of the full associated clinical safety benefits.  

.  

There are however some important considerations which must be addressed prior to switching to Tall man lettering.  

  1. Tall Man lettering should be applied to all clinical systems at the same time to assure the full clinical safety benefits are realised. When health care professionals must work with both tall man and non-tall man versions of the same drugs the cognitive burden is increased. This would include for example inpatient EPMA systems, dispensing systems and Aseptics systems.  
  1. Tall Man for all drugs or just SACT drugs identified by BOPA? IQ HealthTech would recommend that Tall man lettering is adopted for all appropriate drugs according to the ISMP standards to realise the full clinical safety benefits.  
  1. Standardisation of Tall Man lettering method across organisation and any third-party suppliers is recommended.
  1. A process for any new drugs added to the drug formulary to be considered for LASA errors and tall man to be applied as appropriate.  

‍

About iQ HealthTech

iQ HealthTech was established in 2011 by a founding-team of software developers and a practicing consultant oncologist. With a team of subject experts working across design, development, implentations and customer success, the company develops people-centric technology with the goal of improving patient outcomes, everywhere. The company delivers innovative Saas and standalone platforms, including iQemo – the industry-leading, end-to-end chemotherapy prescribing and management platform used by NHS and private hospitals in the UK, and a growing number of hospitals worldwide. Learn more

We’re working on an innovative future for healthcare technology

Sign up to our newsletter and stay updated with industry-leading advice, insight and more…

Thank you! Your submission has been received!
Sorry, something went wrong while submitting the form.

About iQemo

iQemo, from iQHealthTech, provides specialist chemotherapy prescribing. A complete end-to-end solution that includes predefined regimens, prescribing, scheduling and dispensing, through to chemotherapy administration and reporting. iQemo is used in NHS Trusts and private hospitals in the UK, and in a growing number of hospitals worldwide. Learn More

About iQ HealthTech

iQ HealthTech was established in 2011 by a founding-team of software developers and a practicing consultant oncologist. With a team of subject experts working across design, development, implentations and customer success, the company develops people-centric technology with the goal of improving patient outcomes, everywhere. Learn more

Would you like more information about iQemo?

We'd love to discuss how iQemo could support your organisation, people and patients.

Get in touch